Solmaz Sahebjam MD

Hematologic Oncology, Neuro-Oncology

Director of Neuro-oncology Program in National Capital Region, Deputy Director of Clinical Research in National Capital Region, Associate Professor (PAR) of Oncology

Join to View Full Profile

5255 Loughboro Road NorthwestWashington, DC 20016
Phone+1 202-660-6500
Fax+1 202-660-6501

Education & Training

St Vincent HospitalResidency, Internal Medicine, 2006 - 2008
Lincoln Medical and Mental Health CenterResidency, Internal Medicine, 2005 - 2006
Iran University of Medical SciencesClass of 2000

Certifications & Licensure

DC State Medical License 2022 - 2027
FL State Medical License 2013 - 2025
MD State Medical License 2023 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology
Royal College of Physicians and Surgeons of CanadaBoard of Internal Medicine
Royal College of Physicians and Surgeons of CanadaBoard of Medical Oncology

Clinical Trials

A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients Start of enrollment: 2014 Feb 07
COMPLETED
PHASE3
Safety & Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy Start of enrollment: 2014 Jan 01
Terminated
Phase 2
Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction Start of enrollment: 2014 Mar 10
COMPLETED
PHASE1
Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases Start of enrollment: 2014 Oct 09
Terminated
Phase 1
Hypofractionated Stereotactic Irradiation (HFSRT) With Pembrolizumab and Bevacizumab for Recurrent High Grade Gliomas Start of enrollment: 2015 Jul 28
Completed
Phase 1
Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma Start of enrollment: 2018 Mar 16
Completed
Phase 1
IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors Start of enrollment: 2019 Feb 13
Completed
Phase 1
Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease Start of enrollment: 2020 Dec 10
RECRUITING
PHASE1, PHASE2
Join now to see all

Publications & Presentations

PubMed

A sample size analysis of a mathematical model of longitudinal tumor volume and progression-free survival for Bayesian individual dynamic predictions in recurrent high...
Daniel J Glazar, Solmaz Sahebjam, Hsiang-Husan M Yu, Dung-Tsa Chen, Menal Bhandari
CPT. 2025-03-01
Phase 1 trial of hypofractionated stereotactic re-irradiation in combination with nivolumab, ipilimumab, and bevacizumab for recurrent high-grade gliomas.
Solmaz Sahebjam, Raju R Raval, Peter A Forsyth, Heiko Enderling, Nam D Tran
Neuro-Oncology Advances. 2025-02-08
The COVID-19 pandemic experience for patients with central nervous system tumors: Differences in patient-reported outcomes and practice recommendations.
Amanda L King, Kayla N Roche, Elizabeth Vera, Valentina Pillai, Lily Polskin
Neuro-Oncology Practice. 2025-02-01

Journal Articles

Effect of Nivolumab vs Bevacizumab in Patients with Recurrent Glioblastoma
David A Reardon, Antonio Omuro, Joachim Baehring, Surasak Phuphanich, Solmaz Sahebjam, JAMA Oncology

Authored Content

Effect of Nivolumab vs Bevacizumab in Patients with Recurrent GlioblastomaMay 2020
Effect of Nivolumab vs Bevacizumab in Patients with Recurrent GlioblastomaMay 2020
Effect of Nivolumab vs Bevacizumab in Patients with Recurrent GlioblastomaMay 2020